Imiject (Sumatriptan Succinate)

Sumatriptan succinate is a selective agonist of the 5‑HT1B and 5‑HT1D serotonin receptors. By stimulating these receptors, it causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides from trigeminal nerve endings, interrupting the migraine pain pathway.

The dose of Imiject is determined by the prescribing healthcare professional based on the patient’s clinical condition, prior response to therapy, and any contraindications. The prescriber will select the appropriate amount and frequency according to approved labeling and individual patient needs.

Safety data for sumatriptan succinate in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Imiject product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Imiject belongs to the triptan class, which provides rapid, targeted relief by acting on serotonin receptors. Compared with non‑specific analgesics, triptans like sumatriptan have a higher efficacy for moderate to severe migraine attacks, but they are contraindicated in certain cardiovascular conditions where other treatments may be preferred.

Imiject should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and ensure optimal efficacy.

Imiject is supplied as a sterile solution for subcutaneous injection. It is typically administered by a healthcare professional or trained individual using a pre‑filled syringe, injecting into the abdominal wall or thigh according to the prescriber’s instructions.

Serious risks include coronary vasospasm leading to chest pain or myocardial ischemia, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic drugs. Immediate medical attention is required if any of these symptoms occur.

Imiject is contraindicated in patients with known hypersensitivity to sumatriptan or other triptans, those with uncontrolled hypertension, significant cardiovascular disease (e.g., recent myocardial infarction, severe coronary artery disease), and individuals currently taking MAO inhibitors or ergot alkaloids.